KOSDAQElectrical Equipment290690

Solux

₩3,155▲ 23.24%2026-11-18 close
Market Cap
₩167.4B
Turnover
₩39.8B
Volume
13M
Shares out.
53.1M
PER
11.9×
PBR
1.6×
EPS
₩299
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses persist as Solux pivots toward a biotech group

Revenue and operating results have weakened again since the 2023 operating profit, and Solux, renamed in June 2026, is now positioning itself as a biotech-centered holding company.

  1. 1

    Revenue peaked at KRW 59.8 billion in 2023, then fell to KRW 50.7 billion in 2024 and KRW 38.3 billion in 2025, a two-year decline.

  2. 2

    Operating losses were recorded in 2024 and 2025, and the 2025 operating margin of -17.6% was the lowest of 2022 to 2025.

  3. 3

    Operating losses have been recorded for three consecutive quarters from Q1 2026 to Q3 2026, and press reports say the first-half 2026 profit came from an impairment reversal on an affiliate stake.

  4. 4

    Affiliate AriBio has completed the global Phase 3 trial of AR1001, its Alzheimer's candidate, which the group presents as the core of its biotech growth.

  5. 5

    The debt ratio was 55.8% at end-2025, but a KRW 60.6 billion convertible bond and collateral on factory and subsidiary stakes are cited as financial burdens.

02

Business structure

Solux (AriBio Holdings) is a lighting and electrical company founded in July 1996, reporting two segments: a lighting segment and a construction segment.

Its lighting business centers on LED luminaires, outdoor lighting and sports and golf-course lighting, and it entered the Korea Expressway Corporation market through an ESCO business in 2019.

Its construction business holds electrical, information and communication, and fire-safety construction licenses and bids for public and private projects.

Based on the wisereport breakdown, the main product mix was construction (trading) 32.27 percent, LED lighting products 25.89 percent, trading goods 16.90 percent, outdoor lighting products 15.58 percent and other 9.36 percent, and the 2025 domestic share was shown as 100 percent.

In June 2026 the company changed its name from Solux to AriBio Holdings to refocus the group on biotechnology. Its affiliate AriBio completed the global Phase 3 trial of AR1001, an oral Alzheimer's candidate, across 13 countries and about 1,535 participants, while Aribiolab handles vaccine and immunity platforms.

Solux itself intends to keep lighting and electrical work as a stable revenue base while improving profitability. In lighting it is grouped with several small lighting makers as similar companies.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩7.9B-₩2.4B−30.9%
2025Q4₩15.5B₩300M2.2%
2026Q1₩7.4B-₩3.1B−41.6%
2026Q2₩10.7B-₩2.8B−25.9%
2026Q3₩9B-₩3.8B−42.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩55.9B-₩4.3B-₩4.3B−7.7%−10.0%57.8%
2023₩59.8B₩500M-₩6.7B0.9%−10.7%156.6%
2024₩50.7B-₩6.6B-₩41B−13.1%−52.3%49.7%
2025₩38.3B-₩6.7B-₩7.7B−17.6%−8.5%55.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On the disclosed annual figures, revenue rose from KRW 55.9 billion in 2022 to KRW 59.8 billion in 2023, up 7.0 percent, then fell to KRW 50.7 billion in 2024, down 15.3 percent, and KRW 38.3 billion in 2025, down 24.5 percent.

Operating results ran from an operating loss of KRW 4.32 billion in 2022 to an operating profit of KRW 516 million in 2023, which turned profitable from a loss, then an operating loss of KRW 6.62 billion in 2024, a swing back into loss, and an operating loss of KRW 6.72 billion in 2025, with the loss persisting and widening.

The operating margin moved from -7.7 percent in 2022 to 0.9 percent in 2023, -13.1 percent in 2024 and -17.6 percent in 2025, so losses grew relative to sales as revenue shrank.

In 2025 the operating loss stayed near the prior-year level even as revenue fell 24.5 percent, which suggests costs did not fall in step with sales.

Net loss attributable to controlling shareholders was KRW 4.33 billion in 2022, KRW 6.7 billion in 2023, KRW 41 billion in 2024 and KRW 7.72 billion in 2025, a loss that persisted in each of the four years from 2022 to 2025.

The 2024 attributable loss of KRW 41 billion was far larger than the KRW 6.62 billion operating loss, pointing to a large non-operating drag. Total net income including non-controlling interests followed the same pattern.

The debt ratio was 57.8 percent in 2022, 156.6 percent in 2023, 49.7 percent in 2024 and 55.8 percent in 2025, when total equity was KRW 90.9 billion and total liabilities KRW 50.7 billion.

Operating cash flow went from KRW 15.7 billion in 2022 to outflows of KRW 3.66 billion in 2023, KRW 6.45 billion in 2024 and KRW 2.7 billion in 2025.

In the quarters, revenue was KRW 7.9 billion in Q3 2025 with an operating loss of KRW 2.44 billion, then KRW 15.5 billion in Q4 2025, up 95.7 percent quarter on quarter, with an operating profit of KRW 342 million.

Q1 2026 revenue was KRW 7.36 billion, down 52.4 percent, with an operating loss of KRW 3.06 billion, followed by KRW 10.7 billion of revenue and an operating loss of KRW 2.75 billion in Q2 2026. Q3 2026 revenue was KRW 8.99 billion, up 13.7 percent year on year, while the operating loss widened to KRW 3.83 billion.

Net income attributable to controlling shareholders was positive in Q4 2025 at KRW 17.9 billion and in Q2 2026 at KRW 11.2 billion, and the last four quarters totaled KRW 14.4 billion.

Press reports attribute the first-half 2026 profit to an impairment reversal of KRW 19.6 billion on the affiliate AriBio stake, and say the pre-tax result excluding that reversal was a loss of about KRW 16.5 billion. Revenue growth in Q3 2026 alongside a wider operating loss shows that core profitability has not yet recovered.

05

Industry analysis

Solux belongs to the electrical equipment sector, but its disclosed business is closer to LED luminaire manufacturing and electrical and communications construction.

Larger sector peers such as LS ELECTRIC, Hyosung Heavy Industries and HD Hyundai Electric center on power equipment, including transformers and distribution gear, so their product areas differ.

Solux's results therefore relate more directly to lighting demand and public and private construction orders than to the grid-equipment order flow of those larger companies. In lighting it is grouped with a set of small lighting makers and is not directly comparable in scale or technology with the largest players.

On technology, it leads a national energy R&D project to develop a DC-based smart LED lighting system linked to distributed power, with a total scope of KRW 20 billion, due through 2027, and it also took part in national R&D on energy saving, smart lighting and metaverse-related work in 2026.

It has said it plans to extend beyond sports lighting into large facilities such as factory warehouses and port facilities. At group level, the company has said it will expand AI data infrastructure and brain-health care businesses.

Sector-wide cycle or price indicators for LED lighting are not covered in the company materials, so the industry position is described through the company's stated business direction.

06

Outlook

The holding company's group targets call for revenue of KRW 200 billion to KRW 300 billion in 2027 to 2028 and KRW 300 billion to KRW 500 billion a year in 2029 to 2030, to be driven by high-value lighting and electrical work, AI data centers, electroceuticals and consumer healthcare.

Measured against the KRW 38.3 billion of revenue disclosed for 2025, these targets are far higher, and they describe a medium-term plan rather than a forecast.

At a vision event on October 1, 2026, the group said it would link Aribiolab's preventive vaccine work, AriBio's drug development and the holding company's investment and health-care businesses.

The lighting segment aims to raise the share of high-value products such as human-centric lighting and medical specialty lighting. Affiliate AriBio has set a target of KRW 1 trillion in revenue for 2030 based on milestones and royalties from AR1001 commercialization, but that target belongs to AriBio, not to Solux.

Press reports said the AR1001 Phase 3 results were due for release in November 2026 and that approval filing is targeted for 2027, although the timing of top-line announcements has been pushed back several times before.

Related headlines also mention a Greenplus acquisition agreement, a possible management overhaul after completion planned for December 2026, and a KRW 500 million open-market share purchase by a vice chairman.

The company's stated plan is to keep lighting and electrical work as a stable base while improving profitability and deploying the resources into biotech assets and overseas expansion.

07

Valuation

PER
11.9×
PBR
1.6×
ROE
16.4%
EPS
₩299
BPS
₩2,259
Dividend per share
₩0

The share price sits at a premium to book net asset value, and earnings-based multiples are hard to compare directly because quarterly results swing between profit and loss.

The KRW 14.4 billion total of net income attributable to controlling shareholders over the last four quarters came from alternating profitable and loss-making quarters.

On the asset side, of the KRW 74.6 billion carrying value of the AriBio stake, KRW 62.9 billion is goodwill, and the reversal that lifted profit was based on an over-the-counter price. A large share of book value therefore rests on goodwill and the affiliate's valuation, which matters when reading asset-based measures.

Current dividend yield is close to nil, so shareholder returns are not a factor in the valuation today. If the planned merger proceeds, the number of shares would more than double, which would change per-share comparisons. The valuation also depends on the AR1001 trial outcome and the progress of the merger.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

A lighting and electrical cash base

Equity stood at KRW 90.9 billion at end-2025 and the debt ratio was 55.8 percent. The company says it will keep lighting and electrical work as a stable revenue base while improving profitability. The group has presented that business's cash flow as the support for its biotech affiliates. Operating cash flow was still an outflow of KRW 2.7 billion in 2025.

Completed Phase 3 trial for AR1001

Affiliate AriBio has completed the global Phase 3 trial of AR1001. Press reports said top-line results were scheduled for release in November 2026. The group has said it will expand its stakes in core biotech affiliates and make strategic investments.

Once the results are public, the commercialization path and the value of the group's biotech assets are both in view.

Insider buying and recent profit flow

A related headline reported a KRW 500 million open-market purchase by vice chairman Sung Su-hyun and linked it to responsible management and corporate value. Net income attributable to controlling shareholders totaled KRW 14.4 billion over the last four quarters. Q4 2025 turned profitable at KRW 17.9 billion. That period should be read alongside one-off items rather than as a clear core recovery.

09

Bear factors

Shrinking revenue and widening operating losses

Revenue fell to KRW 50.7 billion in 2024 and KRW 38.3 billion in 2025, a two-year decline. The 2025 operating margin was -17.6 percent. The Q3 2026 operating loss of KRW 3.83 billion was larger than the KRW 2.44 billion loss of Q3 2025. The widening loss even in a quarter where revenue rose is cited as a bearish factor.

Profit that relies on an affiliate valuation reversal

One press report said the first-half 2026 profit came from a KRW 19.6 billion impairment reversal on the AriBio stake. Excluding that reversal, the report put the first-half pre-tax result at a loss of about KRW 16.5 billion.

The reversal was based on an over-the-counter price, which makes it hard to count as core earnings. Operating losses continuing alongside profitable quarters is a bearish factor.

Convertible bonds, collateral and cash outflows

Press reports said a KRW 60.6 billion CB is secured by factory and subsidiary stakes, with a collateral limit of KRW 32.5 billion. First-half 2026 operating cash flow was an outflow of KRW 6.23 billion, worse than a year earlier. Total liabilities were KRW 50.7 billion at end-2025. Expanding biotech investment while funding capacity is limited is a burden.

10

Risk factors

Biotech trial and commercialization timing

The release date for the AR1001 Phase 3 top-line results has been pushed back several times. Because those results are a core basis for the merger, delays affect the timing of the group's broader strategy. The approval filing is targeted for 2027, but that depends on the results.

The 2030 revenue target of KRW 1 trillion belongs to the affiliate and should be read apart from Solux's own results.

Financing and liquidity

A KRW 60.6 billion CB is in place, with factory and subsidiary stakes pledged as collateral under a KRW 32.5 billion limit. The conversion price of the eighth CB was adjusted after share price declines. Operating cash flow was an outflow of KRW 2.7 billion in 2025 and KRW 6.23 billion in the first half of 2026. Worse financing terms could weigh on both biotech investment and lighting operations.

Merger delay and share dilution

The absorption merger with AriBio has been stalled for more than two years since the board approved it in August 2024. If completed, the merger would issue 58,227,299 new shares, more than doubling the share count. Whether the backdoor listing will be accepted as a qualifying listing has not been settled. Because the shareholder structure would change, the uncertainty for shareholder value is high.

11

What to watch next

  1. Within November 2026 (scheduled per press reports)

    Release of the main AR1001 Phase 3 results. The outcome will shape the commercialization path, the merger rationale and how the group's biotech assets are valued. The release date has slipped several times before.

  2. December 2026

    Follow-up steps on the Greenplus acquisition agreement and the direction of the management overhaul after completion. Once the deal size and acquired businesses are disclosed, the company's business mix and financial burden will change.

  3. End of March 2027 (annual report filing deadline)

    The 2026 annual report will fix full-year revenue, operating results and operating cash flow as disclosed figures. Whether the operating margin improves from -17.6 percent in 2025 is the next checkpoint.

  4. 2027

    The end of the national DC-based smart LED lighting project and actual revenue against the group's 2027 to 2028 target of KRW 200 billion to KRW 300 billion.

12

Overall view

Solux saw revenue decline in both 2024 and 2025 after its 2023 operating profit, and operating losses have continued. Operating losses have run for three consecutive quarters in 2026, and press reports say an affiliate valuation reversal contributed much of the profit in profitable quarters.

On the other side, the lighting and electrical business remains the group's cash base, and affiliate AriBio has completed the global Phase 3 trial of AR1001, which sits at the center of the biotech strategy.

On the financial side, the KRW 60.6 billion CB and collateral are a burden, and operating cash flow stayed negative. Merger delays and the possibility of a much larger share count are further variables for shareholder value.

The next points to track are the AR1001 results expected in November 2026, the Greenplus procedures in December 2026 and the annual report due by the end of March 2027. This report offers no investment opinion, rating or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. thevc.kr
  2. innoforest.co.kr
  3. theinvest.co.kr
  4. view.asiae.co.kr
  5. m.saramin.co.kr
  6. aribiogroup.com
  7. core.asiae.co.kr
  8. news.nate.com
  9. sisajournal-e.com
  10. jobkorea.co.kr
  11. comp.wisereport.co.kr
  12. m.catch.co.kr
  13. medipana.com
  14. leadeconomy.co.kr
  15. saramin.co.kr
  16. newspim.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis